TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)
26 juil. 2022 01h30 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in TG Therapeutics? If so, please visit TG Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Missfresh, Molecular Partners, TG Therapeutics, and 17EdTech and Encourages Investors to Contact the Firm
25 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 25, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TG Therapeutics and 17EdTech and Encourages Investors to Contact the Firm
20 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGTX
20 juil. 2022 13h18 HE
|
The Rosen Law Firm PA
NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of TG...
TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (NASDAQ: TGTX)
19 juil. 2022 16h00 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in TG Therapeutics? If so, please visit TG Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to...
TGTX Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their TG Therapeutics Losses
19 juil. 2022 08h05 HE
|
Johnson Fistel, LLP
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of TG Therapeutics, Inc. (“TG...
Bragar Eagel & Squire, P.C. Is Investigating TG Therapeutics, Allianz, GoodRx, and the WWE and Encourages Investors to Contact the Firm
15 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TG Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Is Investigating Corcept, Rollins, Target, and TG Therapeutics and Encourages Investors to Contact the Firm
10 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Is Investigating TG Therapeutics, Allianz, Outset Medical, and TrueBlue and Encourages Investors to Contact the Firm
04 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TG Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Is Investigating Inotiv, TG Therapeutics, Allianz, and Outset Medical and Encourages Investors to Contact the Firm
29 juin 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inotiv, Inc. (NASDAQ:...